INTRODUCTION
Hematopoietic stem cells (HSCs) have the capacity to self-renew and differentiate into all kinds of hematopoietic and immune cells, 1 even non-blood cells. 2 As a portion of lineage-negative (Lin À ), Sca-1 (stem cells antigen-1)-positive and c-Kit (CD117)-positive cells (LSK cells) containing hematopoietic stem and progenitor cell pool, 3, 4 HSCs primarily reside in a highly complex microenvironment of the bone marrow. 5, 6 Due to their hematopoietic-generating properties, HSCs and hematopoietic progenitor cells have been widely used as autologous or allogeneic transplants to treat patients with blood disorders and hematopoietic malignancies. 7, 8 However, following transplantation, patients may remain cytopenic and immune defective, with accrued mortality risk arising from engraftment failure, opportunistic infection, and disease relapse. 9, 10 During the last decade, remarkable progress has been made in developing new tools to manipulate HSCs and hematopoietic progenitor cells for clinic use. G-CSF (granulocyte colony-stimulating factor), GM-CSF (granulocyte macrophage colony-stimulating factor), and CXCR4 (C-X-C chemokine receptor type 4) antagonists have been utilized to mobilize HSC migration from bone marrow to the blood and increase the number of myeloid progenitors. 11, 12 Although these agents can mobilize HSCs to facilitate the harvest of the cells from peripheral blood, they do not lead to expansion of endogenous selfrenewing HSCs. An integrated strategy by automated control of inhibitory feedback signaling can expand HSCs ex vivo. 13 Using alexidine dihydrochloride and metformin to reprogram HSC metabolism or inhibiting retinoic acid signaling can facilitate the maintenance of HSCs in vitro and promote their self-renewal. 14, 15 Notch, Wnt/b-catenin, Bmi-1 (B lymphoma Mo-MLV insertion region 1 homolog), HoxB4 (homeobox B4), and aryl hydrocarbon receptor antagonists have all been shown to promote the expansion of HSCs and progenitor cells in vitro. [16] [17] [18] [19] [20] However, in vitro-expanded HSCs have decreased engraftment capacity. 21, 22 Until now, there has been no effective method to expand endogenous HSCs in vivo for repopulation of hematopoietic cells and immune system.
GM-CSF and interleukin (IL) common gamma chain cytokine-based fusion genes (GIFT fusokines) have been shown to have novel biological functions distinct from their parental molecules, 23, 24 inducing regulatory B cells, 25 tumor-killing dendritic cells, 26 and natural killer cells. 27 Recently, we generated a synthetic fusokine that is derived from the fusion of GM-CSF and IL-4 (named as GIFT4) and found that GIFT4 protein has a potent immune stimulatory property and educates naive B cells into B effector cells with anti-tumor activity. 28 Unexpectedly, we discovered that GIFT4 triggers a novel B cell function on hematopoiesis in vivo. Here, we show that GIFT4 treatment expands endogenous LSK cells and its subpopulations, HSCs and multipotent progenitors (MPPs), in a B cell-dependent manner and robustly accelerates long-term hematopoietic reconstitution following myeloablative therapy in mice.
RESULTS

GIFT4 Induces the Endogenous Expansion of Bone Marrow LSK Cells
We previously demonstrated that GIFT4, a fusion protein from GM-CSF and IL-4 with a single polypeptide chain of 282 amino acids ( Figure 1A ), has a potent immune stimulatory function on B cells. 28 Surprisingly, delivery of GIFT4 protein into naive C57BL/6J (B6) mice significantly increased bone marrow cellularity ( Figure S1 ) and the proportion of endogenous LSK cells in the Lin-negative population of bone marrow cells in comparison with GM-CSF and IL-4 treatment or PBS controls, as determined by fluorescence-activated cell sorting (FACS) assay ( Figure 1B ). The percentage of LSK cells in the femur of GIFT4-treated mice was 5.8% on average, 2.5-fold higher than the ones in GM-CSF and IL-4-or PBS-treated mice (2.3% and 2.2% on average, respectively) ( Figure 1C ). There was no significant difference in LSK cell percentage between the two control groups ( Figures 1B and 1C ). In comparison with mice treated with GM-CSF and IL-4 or PBS, GIFT4-treated mice had a significant increase in the absolute number of LSK cells ( Figure 1D) 1F ). However, GIFT4-treated mice had more than a 5-fold increase of LT-HSC, ST-HSC, or MPP cell numbers per femur in comparison with the PBS-treated group ( Figure 1G ). There was no significant difference in the cell number of LT-HSCs, ST-HSCs, or MPPs in mice treated with GM-CSF and IL-4 or PBS ( Figure 1G ). Peripheral blood counts showed that GIFT4-treated mice had similar peripheral blood profiles on the compartments of white blood cells, red blood cells, and + platelets with GM-CSF and IL-4-or PBS-treated mice or naive mice ( Figure 1H ). Ki67 is a cell proliferation marker and has been utilized to analyze the cell cycle status of HSCs. 29 To determine whether GIFT4 stimulation could trigger the proliferation of bone marrow HSCs and MPPs in vivo, we performed intracellular staining of Ki67 on bone marrow cells isolated from GIFT4-treated mice. FACS analyses revealed that GIFT4 treatment markedly promoted the proliferation of endogenous bone marrow LT-HSCs, ST-HSCs, and MPPs in the treated mice in comparison with GM-CSF and IL-4 or PBS treatment ( Figures S2A and S2B ). In contrast, there were no Ki67 + LT-HSCs and a very low percentage of Ki67 + ST-HSCs or MPPs in mice treated with GM-CSF and IL-4 or PBS ( Figures S2A  and S2B ). Annexin-V staining of LSK cells showed that GIFT4 treatment also led to a higher percentage of apoptotic death in LT-HSCs compared with ST-HSCs and MPPs ( Figures S2A and S2C) .
B Cells Are Essential for GIFT4-Induced LSK Expansion In Vivo
To test our hypothesis that B cells may play an important role in GIFT4-augmented hematopoietic regeneration, we utilized B celldeficient m-chain mutant transgenic (mMT) mice that lacked functional B cells but had normal T cell and other immune cellular compartments. mMT mice were treated with GIFT4 protein, control cytokines GM-CSF and IL-4, or PBS. Analysis of LSK cells in the bone marrow of treated mice by FACS showed that there was no significant difference in the LSK cell percentage in the Lin À population among the three groups of treated mice, and GIFT4 treatment could not promote the expansion of endogenous LSK cells in the absence of B cells (Figures 2A and 2B ). The absolute number of bone marrow LSK cells per femur was similar among the three groups of mice treated with or without GIFT4 protein ( Figure 2C ). To examine whether B cells are required for GIFT4-triggered expansion of HSCs and MPPs, we analyzed the three components of LSK cells in the treated mMT mice. The profile of LSK cell subsets in GIFT4-treated mice demonstrated that GIFT4 stimulation could not increase endogenous LT-HSCs, ST-HSCs, and MPPs in the absence of functional B cells ( Figure 2D ). To test whether the adoptive transfer of B cells could facilitate LSK cell expansion in the bone marrow of mMT mice upon GIFT4 stimulation, we purified splenic B cells from naive B6 mice with a B cell-negative selection kit with the addition of anti-mouse Sca1 and c-Kit antibodies to remove LSK cells in purified B cells. mMT mice that received purified B cells were then treated with GIFT4, GM-CSF and IL-4, or PBS. The profile of LSK cells in the three groups of treated mice demonstrated that GIFT4 treatment significantly increased bone marrow LSK cells in the mMT mice adoptively transferred with naive B cells, which was five times higher than in the mice treated with GM-CSF and IL-4 or PBS ( Figure 2E ). Consistently, administration of GIFT4 protein significantly increased the number of LT-HSCs, ST-HSCs, and MPPs in B cell-transferred mMT mice in comparison with GM-CSF and IL-4-or PBS-treated mMT mice ( Figure 2F ). To examine the hematopoietic capability of GIFT4-triggered LSK cells, lethally irradiated B6 mice were transplanted with LSK cells ( Figure S3A ). Blood counting and mice body weight change demonstrated that mice that received GIFT4-augmented LSK cells had similar hematopoietic regeneration ( Figure S3B ) and body weight recovery ( Figure S3C ) and survived ( Figure S3D ), in comparison with mice transferred with normal LSK cells ( Figures S3B-S3D ). PBS-treated mice died from hematopoietic failure within 2 weeks after irradiation ( Figures S3B  and S3D ).
Blocking B Cell-Derived Leukines Suppresses GIFT4-Induced HSC Expansion
We previously showed that GIFT4-treated B cells (GIFT4-B cells) produce a panel of leukines, including IL-1, IL-6, GM-CSF, CCL3 (C-C motif chemokine ligand 3), and VEGF (vascular endothelial growth factor). To test whether GIFT4 treatment could increase bone marrow LT-HSCs, ST-HSCs, and MPPs in vitro and whether those leukines contribute to the augmentation of HSCs and MPPs, we stimulated bone marrow cells with GIFT4, GM-CSF and IL-4, or PBS for 4 days or with GIFT4 protein in the presence or absence of specific neutralizing antibodies against those leukines. The profile of the three LSK components by FACS demonstrated that GIFT4 treatment significantly increased the percentage and absolute cell number of LT-HSCs or ST-HSCs in the cell culture system in comparison with GM-CSF and IL-4 or PBS treatment ( Figures 3A and 3B ). There were few MPPs in GIFT4-treated bone marrow cells (Figure 3B ). Blocking the activities of IL-1, IL-6, GM-CSF, CCL3, or VEGF by the addition of specific neutralizing antibodies in the GIFT4 and bone marrow cell culture system significantly reduced the number of LT-HSCs and ST-HSCs in the culture ( Figure 3C ), although neutralizing antibodies had no significant effect on the proportion of HSCs and MPPs in the LSK compartment ( Figure S4 ). Interestingly, the combination of those neutralizing antibodies further suppressed HSCs in comparison with individual antibody ( Figure 3C ). However, anti-mouse IL-2-neutralizing antibodies had no suppressive effect on GIFT4-mediated HSC augmentation (Figure 3C ). To further examine whether neutralizing the activity of GIFT4-B cell-secreted cytokines could have a suppressive effect on HSCs, GIFT4-B cells were co-cultured with sorted LSK cells in the presence of these antibodies for 4 days. Indeed, antibodies against IL-1, IL-6, GM-CSF, CCL3, or VEGF, but not IL-2, significantly reduced the number of LT-HSCs or ST-HSCs in the cell culture system in comparison with control immunoglobulin G (IgG) treatment ( Figure 3D ).
Administration of GIFT4 and B Cells Augments Hematopoietic Regeneration
To test whether GIFT4 protein could serve on its own as a hematopoietic augmenter to restore the blood system after lethal irradiation, we radiated B6 mice with a dose of 11Gy and treated mice with GIFT4 protein or purified B cells only or GIFT4 protein plus B cells or PBS ( Figure 4A ). Mice did not receive any bone marrow or LSK cells www.moleculartherapy.org as hematopoietic rescue. Monitoring murine body weight demonstrated that the delivery of GIFT4 protein plus B cells into radiated mice promoted body weight recovery on day 124 after irradiation ( Figure 4B ) and long-term survival ( Figure 4C ). In contrast, mice that received GIFT4, B cells only, or PBS continued to lose weight ( Figure 4B ) and died from bone marrow failure within 2 weeks after irradiation ( Figure 4C ). Peripheral blood counting showed that the delivery of GIFT4 protein to the mice did not prevent pancytopenia caused by lethal irradiation, and mice had a very low number of blood cells on day 13 after irradiation, similar to the mice treated with B cells only or PBS ( Figure 4D ). However, mice administrated with GIFT4 protein and naive B cells had a significantly higher number of blood cells in the circulation on day 13, compared to the ones treated with GIFT4 protein or B cells alone or PBS ( Figure 4D ). On day 124 after irradiation, mice treated with GIFT4 plus B cells had almost complete hematopoietic regeneration, with similar levels of white blood cells, red blood cells, platelets, and hemoglobin in the circulation as the baseline before irradiation ( Figure 4E ). Adoptive transfer of LSK cells from GIFT4 and B cell-treated mice into naive irradiated B6 mice further confirmed its hematopoietic capability similar to LSK cells isolated from naive B6 mice ( Figure S5 ).
GIFT4-B Cells Enable Hematopoietic Recovery in Irradiated Mice
To explore the potential of GIFT4-B cells as an autologous cell therapy, we produced GIFT4-B cells in vitro and adoptively transferred the cells or syngeneic bone marrow cells, naive B cells (Figure S6A ), or T cells into radiated mice (11Gy) on day 1 and day 4. GIFT4-B cells, as well as purified naive B cells, are absent of LSK cells (Figure S6B) and express a panel of B effector markers ( Figure S6C ), as we previously showed. 28 GFP-positive GIFT4-B cells have the capability to migrate into the bone marrow and spleen, but not the brain, in vivo ( Figures S6C and S6D ). The measurement of body weight showed that the delivery of GIFT4-B cells prevented mice from irradiation-induced body weight loss ( Figure 5A) ; the mice continued to gain weight and survived similarly to bone marrow-transferred mice ( Figure 5B). However, control mice that received normal B cells, T cells, or PBS treatment failed to recover from body weight loss and died ( Figures 5A and 5B ). Peripheral blood counts on day 124 after irradiation further confirmed that GIFT4-B cell treatment www.moleculartherapy.org completely restored hematopoiesis in mice ( Figure 5C ). Analyses of T cell and B cell components in peripheral blood in mice treated with GIFT4-B cells or bone marrow cells on day 124 after irradiation demonstrated that GIFT4-B cell treatment promoted T cell and B cell recovery close to the one in bone marrow-transplanted mice or the baseline level before irradiation ( Figures 5D and 5E ). Bone marrow cellularity in mice that received GIFT4-B cells and bone marrow cells were similar ( Figure 5F ). There was also no significant difference in the profiles of LSK cells ( Figure 5G ) and the three subsets between GIFT4-B cell-treated mice and bone marrow-transferred mice ( Figures 5H and 5I) . Transplantation of LSK cells from GIFT4-B cell-treated mice into irradiated B6 mice further confirmed the hematopoietic ability of the LSK cells similar to the ones isolated from naive mice ( Figure S5 ).
To test whether allogeneic GIFT4-B cells could function similarly as autologous GIFT4-B cells in hematopoiesis, we generated GIFT4-B cells from GFP-positive B6 mice, and adoptively transferred the GFP + GIFT4-B cells into B6D2F1/J mice (allogeneic to B6 mice) 30 as stated above ( Figure 6A ). FACS analysis showed that seven times more GFP + GIFT4-B cells than GFP + naive B cells entered into the bone marrow within 48 hr after intravenous injection ( Figure 6B ). We also transferred GFP-positive bone marrow cells isolated from GFP + mice into radiated mice serving as positive control treatment. Measurement of mouse body weight showed that mice receiving allogeneic GIFT4-B cells prevented mice from losing weight after irradiation, which was slightly lower than mice that received GFP + bone marrow cells. Both groups of mice survived lethal irradiation for a long-term period (124 days) ( Figures 6C and 6D) . Consistently, PBS-treated mice or mice transferred with normal B cells failed to gain weight and died ( Figures 6C and 6D) . Peripheral blood counting showed that allogeneic GIFT4-B cell-treated mice had similar levels of white blood cells, red blood cells, platelets, and hemoglobin levels as bone marrow-transplanted mice on day 124 after irradiation, which recovered to the baseline level before irradiation ( Figure 6E ). FACS analysis on peripheral blood further showed that white blood cells in mice that received GFP + bone marrow were 99.2% GFP positive ( Figure 6F ), confirming hematopoietic recovery came from donor LSK cells. However, white blood cells in mice adoptively transferred with allogeneic GFP + GIFT4-B cells were 99.9% GFP negative ( Figure 6F ), demonstrating that long-term hematopoietic regeneration after lethal irradiation was derived from endogenous autologous HSCs.
DISCUSSION
In this study, we demonstrated that GIFT4 fusokine induces B cellmediated expansion of endogenous LSK cells in bone marrow and GIFT4-B cells promote hematopoietic regeneration in a murine model of irradiation-induced hematopoietic failure. To our knowledge, it is the first report that an engineered cytokine triggers a previously undescribed B cell function on hematopoiesis, which supports the new concept that B cells are involved in the process of hematopoietic regeneration.
The bone marrow niche consists of stromal cells, endothelial cells, osteoblasts, B cells, and other immune cells, [31] [32] [33] which regulate the proliferation, differentiation, and mobilization of HSCs. 31, 32 As a heterogeneous population in bone marrow microenvironment, 34 B cells have been shown to act as the main osteoprotegerin producer in bone marrow for maintaining bone basal homeostasis in vivo 35 and play a role in the mobilization of HSCs. 36 However, whether B cells play a role in hematopoiesis or hematopoietic regeneration remains unclear. In the clinic, anti-CD20 antibody rituximab therapy to deplete B cells for the treatment of patients with B cell lymphoma and autoimmune diseases often causes white cell maturation arrest, the lack of granulocyte progenitors, and hypocellularity in the bone marrow niche, Cytokines, chemokines, and growth factors, such as IL-1, IL-3, IL-6, stem cell factor (SCF), GM-CSF, G-CSF, and VEGF produced by the cellular components in the bone marrow stem cell niche contribute to HSC self-renewal, expansion, and differentiation. G-CSF has been shown to activate dormant HSCs into selfrenewal. 40 IL-6 has be demonstrated to have a synergetic effect with other cytokines and growth factors, including IL-3 and SCF, to expand HSCs in vitro or ex vivo. 41, 42 A single-cell proteomics platform showed that IL-6 is particularly important for regulating myeloid differentiation and the proliferation of hematopoietic stem and progenitor cells; neutralizing IL-6 or GM-CSF reduces the number of LSK cells. 43 VEGF is required for adult HSC formation and survival 44 and is essential for erythropoiesis. 45 Murine GIFT4-B cells produce an array of hematopoietic cytokines and growth factors, including IL-1, IL-6, GM-CSF, VEGF, and chemokine CCL3, but not G-CSF and SCF. 28 The role of CCL3 on hematopoiesis is controversial. In the presence of GM-CSF or M-CSF or in combination with SCF, IL-3, IL-6, and Flt3L, CCL3 has a stimulatory effect on the expansion and proliferation of hematopoietic progenitor cells. 46, 47 However, CCL3 together with transforming growth factor b (TGF-b), CCL2, CCL4, and CXCL10 showed an inhibitory effect on HSC expansion. 13 Our data demonstrate that inhibiting the activities of IL-1, IL-6, GM-CSF, CCL3, or VEGF by neutralizing antibodies significantly reduced GIFT4-and GIFT4-B cell-augmented LT-HSCs and ST-HSCs in vitro, suggesting that the aggregate pool of pro-hematopoietic secretome, consisting of IL-1, IL-6, VEGF, GM-CSF, and CCL3 from GIFT4-B cells, could contribute to GIFT4-induced B cell-dependent expansion of HSCs in vivo.
GIFT4-B cells possess unique secretion of pro-hematopoietic growth factors, cytokines, and chemokines. 28 It was reported that GM-CSF promoted hematopoietic recovery by enhancing the survival of HSCs and the proliferation and differentiation of myeloid lineage cells in irradiated mice. 48, 49 Cytokines IL-1 and IL-12 also have pro-hematopoietic effects, enhancing hematopoiesis and immune reconstitution following irradiation. [50] [51] [52] [53] Chemokine CCL3 has been shown to help hematopoietic recovery after several cycles of radiation therapy by maintaining the self-renewal capacity of HSCs. 54 Growth factor VEGF was reported to have mitogenic activity to suppress HSC apoptotic death and play a role in the survival and maintenance of HSCs. 55 Indeed, the delivery of autologous or allogeneic GIFT4-B cells rescued the irradiated mice from hematopoietic injury and augmented hematopoietic regeneration and long-term survival. By blocking the activities of GIFT4-B cell secretome with specific neutralizing antibodies abrogated the pro-hematopoietic function of GIFT4-B cells on HSCs. Conversely, naive B cells or GM-CSF and IL-4-treated B cells do not produce IL-1, IL-6, VEGF, GM-CSF, and CCL3, 28 and the delivery of naive B cells or B cells plus GM-CSF and IL-4 treatment could not induce the expansion of LSK cells in B cell-deficient mice and failed to repopulate hematopoietic system in irradiated mice, further indicating that GIFT4-B cells have a unique pro-hematopoietic activity.
In summary, our study has identified a previously undescribed novel B cell function that supports hematopoiesis and hematopoietic regeneration. Based on the activities of GIFT4 protein and GIFT4-B cells in tumor 28 and hematopoietic regeneration, we propose that GIFT4 and GIFT4-B cells could serve as means to augment long-term hematopoietic engraftment in the setting of autologous and allogeneic bone marrow transplantation for patients with hematological malignancy.
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MATERIALS AND METHODS
GIFT4 Protein
GIFT4 chimeric transgene was cloned from murine GM-CSF and IL-4 cDNA (Invivogen), and the fusion protein was produced in bio-engineered 293T cells as previously described. 28 Protein was quantified by an ELISA kit with anti-murine GM-CSF antibodies (eBiosciences). 
Flow Cytometry
Bone marrow cells were harvested from the in vitro cell culture system or the femur of B6 mice, B cell-deficient mMT mice (B6.129S2-Igh-6 tm1Cgn /J), or B6D2F1/J mice (Allogeneic to B6) and were stained with peridinin chlorophyll (PerCP)-conjugated anti-mouse Sca-1 allophycocyanin (APC)-conjugated anti-mouse c-Kit, biotinlabeled anti-lineage antibodies (CD2, CD3, CD4, CD8, CD11b, CD11c, CD14, B220, NK1.1, Gr-1, and TER-119) (Biolegend), fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD34, and anti-mouse CD135 (Brilliant Violet 421) for 30 min at 4 C and then reacted with phycoerythrin (PE)-conjugated streptavidin. After a wash with PBS, the cells were subjected to FACS analyses on a BD Canto Flow Cytometer. Alternatively, bone marrow cells harvested from B6 mice were subjected to Annexin-V staining or intracellular staining with PE-conjugated anti-Ki67 antibody (BD) after surface staining with anti-mouse Sca-1, CD117, CD34, and CD135 antibodies. LSK cells were also sorted from the Lin À Sca1
+-c-Kit + cell population in the bone marrow isolated from naive-or GIFT4-treated B6 mice or irradiated mice on a BD Aria Cell Sorter for in vitro or in vivo experiments. For determining the initiation of hematopoietic recovery from endogenous or exogenous LSK cells, irradiated B6D21/J mice were treated with GFP + GIFT4-B cells or GFP + bone marrow cells. Peripheral blood cells, splenocytes, and bone marrow cells were harvested from treated mice. After lysis of red blood cells, leukocytes were subjected to FACS analyses with anti-CD3 or B220 antibodies (BD), and GFP-positive cells were also gated. All FACS data were analyzed with FlowJo 9.1 software.
Blood Cell Counting
Peripheral blood was harvested from B6, mMT, or B6D2F1/J mice directly to microvette tubes containing ethylenediaminetetraacetic acid-tripotassium salt (Sarstedt) and subjected to blood cell counting on a Vet-ABC Animal Blood Counter (Scil) using a mouse software provided by the company.
Mouse Experiments
Naive B6 and mMT mice were treated with GIFT4, GM-CSF and IL-4 (20 ng/mouse/day), or PBS by intravenous injection for 6 days (10 mice per group). Femurs were harvested for LSK cell analysis. For mouse total body irradiation to induce bone marrow failure, naive B6 or B6D2F1/J mice were treated with a dose of 11Gy total body irradiation (5.5Gy + 5.5Gy with a 3 hr interval) as previously described. 
Statistical Analysis
Data were shown as mean ± SEM. p values were calculated using the one-way analysis of variance test. A p value of less than 0.05 was considered significant (*p < 0.05; **p < 0.01; ***p < 0.001). 
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